TechFlow news, on November 21, Israeli clinical-stage immunotherapy company Enlivex Therapeutics announced that its board of directors has approved allocating up to $1 million to purchase Bitcoin as part of its cash management strategy.
Listed on the NASDAQ in the United States (ticker: ENLV), CEO Oren Hershkovitz stated that with growing demand for and adoption of Bitcoin, along with recent approval of Bitcoin ETFs and institutional investor support, the company views Bitcoin as a strong reserve asset offering value storage and inflation resistance.




